FOLH1 and metastatic prostate carcinoma: The bifunctional chelator HBED-CC is used clinically in the peptide-based 68Ga-labelled radiopharmaceutical, 68Ga-HBED-PSMA, which targets the prostate specific membrane antigen expressed in metastatic prostate cancer [6].